ATE355846T1 - Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält - Google Patents

Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält

Info

Publication number: ATE355846T1
Authority: AT; Austria
Prior art keywords: orotate; vitamin; gluconate; pharmaceutical composition; composition containing
Prior art date: 1999-10-04

Application number

AT00964469T

Other languages

English (en)

Inventor

John Carter

Original Assignee

John Carter

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-10-04

Filing date

2000-10-02

Publication date

2007-03-15

1999-10-04 Priority claimed from GBGB9923431.2A external-priority patent/GB9923431D0/en

2000-06-13 Priority claimed from GB0014420A external-priority patent/GB0014420D0/en

2000-10-02 Application filed by John Carter filed Critical John Carter

2007-03-15 Application granted granted Critical

2007-03-15 Publication of ATE355846T1 publication Critical patent/ATE355846T1/de

Links

CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 title abstract 3
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 title 2
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 title 1
229910052802 copper Inorganic materials 0.000 title 1
239000010949 copper Substances 0.000 title 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
229960004889 salicylic acid Drugs 0.000 title 1
QOOMRZNLVISVGR-UHFFFAOYSA-L 2,4-dioxo-1h-pyrimidine-6-carboxylate;iron(2+) Chemical compound [Fe+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 QOOMRZNLVISVGR-UHFFFAOYSA-L 0.000 abstract 1
VNHIRKVBSRYPGG-UHFFFAOYSA-L 2,4-dioxo-1h-pyrimidine-6-carboxylate;manganese(2+) Chemical compound [Mn+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 VNHIRKVBSRYPGG-UHFFFAOYSA-L 0.000 abstract 1
OCUCCJIRFHNWBP-IYEMJOQQSA-L Copper gluconate Chemical compound [Cu+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OCUCCJIRFHNWBP-IYEMJOQQSA-L 0.000 abstract 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract 1
ABBQHOQBGMUPJH-UHFFFAOYSA-M Sodium salicylate Chemical compound [Na+].OC1=CC=CC=C1C([O-])=O ABBQHOQBGMUPJH-UHFFFAOYSA-M 0.000 abstract 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
229930003268 Vitamin C Natural products 0.000 abstract 1
WHMDKBIGKVEYHS-IYEMJOQQSA-L Zinc gluconate Chemical compound [Zn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O WHMDKBIGKVEYHS-IYEMJOQQSA-L 0.000 abstract 1
230000000118 anti-neoplastic effect Effects 0.000 abstract 1
229940034982 antineoplastic agent Drugs 0.000 abstract 1
229940108925 copper gluconate Drugs 0.000 abstract 1
WKQFGWKSVRJAMI-UHFFFAOYSA-L copper;2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [Cu+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 WKQFGWKSVRJAMI-UHFFFAOYSA-L 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 abstract 1
235000014012 manganese gluconate Nutrition 0.000 abstract 1
239000011683 manganese gluconate Substances 0.000 abstract 1
229940072543 manganese gluconate Drugs 0.000 abstract 1
OXHQNTSSPHKCPB-IYEMJOQQSA-L manganese(2+);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Mn+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O OXHQNTSSPHKCPB-IYEMJOQQSA-L 0.000 abstract 1
230000001613 neoplastic effect Effects 0.000 abstract 1
229960004025 sodium salicylate Drugs 0.000 abstract 1
235000019154 vitamin C Nutrition 0.000 abstract 1
239000011718 vitamin C Substances 0.000 abstract 1
235000011478 zinc gluconate Nutrition 0.000 abstract 1
239000011670 zinc gluconate Substances 0.000 abstract 1
229960000306 zinc gluconate Drugs 0.000 abstract 1
229940046253 zinc orotate Drugs 0.000 abstract 1
YNMDOZLVAPMCBD-UHFFFAOYSA-L zinc;2,4-dioxo-1h-pyrimidine-6-carboxylate Chemical compound [Zn+2].[O-]C(=O)C1=CC(=O)NC(=O)N1.[O-]C(=O)C1=CC(=O)NC(=O)N1 YNMDOZLVAPMCBD-UHFFFAOYSA-L 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/34—Copper; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nutrition Science (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

AT00964469T 1999-10-04 2000-10-02 Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält ATE355846T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9923431.2A GB9923431D0 (en)	1999-10-04	1999-10-04	Pharmaceutical compositions and their use
GB0014420A GB0014420D0 (en)	2000-06-13	2000-06-13	Pharmaceutical compositions and their use

Publications (1)

Publication Number	Publication Date
ATE355846T1 true ATE355846T1 (de)	2007-03-15

Family

ID=26244470

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00964469T ATE355846T1 (de)	1999-10-04	2000-10-02	Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält

Country Status (13)

Country	Link
US (2)	US7939109B1 (de)
EP (1)	EP1220678B1 (de)
JP (1)	JP2003510363A (de)
AT (1)	ATE355846T1 (de)
AU (1)	AU776732B2 (de)
CA (1)	CA2386423C (de)
CY (1)	CY1106633T1 (de)
DE (1)	DE60033830T2 (de)
DK (1)	DK1220678T3 (de)
ES (1)	ES2283318T3 (de)
GB (1)	GB2356347B (de)
PT (1)	PT1220678E (de)
WO (1)	WO2001024803A2 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2374008B (en) *	2001-04-04	2005-03-16	John Carter	Pharmaceutical compositions comprising copper and zinc
JP2004277379A (ja) *	2003-03-18	2004-10-07	Medicos Hirata:Kk	細胞死誘発ドラッグデリバリーシステム
RU2242976C1 (ru) *	2003-06-18	2004-12-27	Всероссийский научно-исследовательский институт гельминтологии им.К.И. Скрябина	Антигельминтное средство
RU2358721C1 (ru) *	2005-04-15	2009-06-20	Виктор Павлович Кутняк	Антинеопластический препарат (варианты)
DE102005020327A1 (de)	2005-04-30	2006-11-09	Multibind Biotec Gmbh	Dekontaminationslösungen und deren Verwendung zur Denaturierung, Modifikation, Degradation, Solubilisierung und Entfernung von Proteinen, Nukleinsäuremolekülen und Mikroorganismen von Oberflächen
DE102006001213A1 (de) *	2006-01-10	2007-07-12	Multibind Biotec Gmbh	Synergistische Lösung aus Ascobinsäure oder deren Derivaten und Metallionen effizienten, selektiven Abtötung pathologischer Säugerzellen
AU2008239966C1 (en) *	2007-04-13	2012-03-29	Dong Wha Pharmaceutical Co., Ltd.	Aspartate of 1-cyclopropyl-6-fluoro-7-(8-methoxyimino-2,6-diaza- spiro[3.4]oct-6-yl)-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid, method for preparing the same, and antimicrobial pharmaceutical composition comprising the same
MD4132C1 (ro) *	2010-12-13	2012-05-31	Государственный Университет Молд0	Di(µ-S)-bis{cloro-[fenil(piridin-2-il)metanon-tiosemicarbazonato(1-)]cupru} care manifestă proprietatea de inhibare a proliferării celulelor T-47D ale cancerului mamar
DK178786B1 (en) *	2015-03-11	2017-02-06	Dantrace-Danfeed Ivs	Use of zinc and copper gluconate in the treatment of methicillin-resistant staphylococcus aureus
DK178709B1 (en) *	2015-06-17	2016-11-28	Dantrace	APPLICATION OF ZINC AND COPPER GLUCONATES IN THE TREATMENT OF DIGITAL DERMATITIS

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2415740C2 (de) *	1974-04-01	1983-12-01	Servomed Arznei GmbH & Co Pharma KG, 8000 München	Verwendung von Orotsäure bei der analgetischen Behandlung mit Dextropropoxyphen, Natriumsalicylat oder Metamizol
DE2457524A1 (de) *	1974-12-05	1976-06-10	Nadrol Chemie Pharma Keizer Kg	Arzneimittel zur beeinflussung des zinkspiegels im mechanismus des zellstoffwechsels
GB2022998B (en) *	1978-06-14	1982-09-08	Beres J	Phermaceutical composition for the treatment of neoplasticand other diseases
US4616039A (en) *	1979-08-30	1986-10-07	Herschler R J	Methylsulfonylmethane in dietary products
US4514421A (en) *	1979-08-30	1985-04-30	Herschler R J	Dietary and pharmaceutical uses of methylsulfonylmethane and compositions comprising it
EP0145711A1 (de) *	1983-06-10	1985-06-26	International Copper Association, Inc.	Kupferkomplex zum behandeln von krebs
EP0208362A1 (de) *	1985-06-28	1987-01-14	The Procter & Gamble Company	Diätetische Zusatzmittel, enthaltend Eisen sowie mit darmlöslicher Schicht ummanteltes Calcium
US4853377A (en) *	1985-10-15	1989-08-01	Pollack Robert L	Method and composition for increasing production of serotonin
AU1799588A (en) *	1987-05-11	1988-12-06	Procyte Corporation	Method of tumor inhibition in warm-blooded animals
FI892006A7 (fi) *	1988-04-29	1989-10-30	Phil Gold	Laktalbumiini ruoan lisäaineena
IT8947616A0 (it) *	1989-02-06	1989-02-06	Verde Giancarlo Umberto	Preparato per il trattamento e la cura delle emorroidi
JPH02227048A (ja) *	1989-03-01	1990-09-10	Sumitomo Cement Co Ltd	食品用カルシウム補給剤
JP2818892B2 (ja) *	1989-10-02	1998-10-30	大塚製薬株式会社	発泡製剤
US6451341B1 (en) *	1990-02-05	2002-09-17	Thomas J. Slaga	Time release formulation of vitamins, minerals and other beneficial supplements
FR2675996B1 (fr) *	1991-04-30	1993-10-15	Georges Baritiu	Compositions sanogenes dietetiques complexes.
JPH06199696A (ja) *	1992-03-06	1994-07-19	Yunie:Kk	制癌・抗癌剤
IL110139A0 (en) *	1993-06-28	1994-10-07	Howard Foundation	Pharmaceutically-active antioxidants
US5639787A (en) *	1995-02-28	1997-06-17	The Center For The Improvement Of Human Functioning Int'l, Inc.	Therapeutic method for the treatment of cancer
EP0853486A4 (de) *	1995-09-25	2001-09-26	Samir Chachoua	Therapeutische anwendungen von tierischen seren einschliesslich von pferdeseren in der behandlung von aids, krebs, und anderen viralen oder bakteriellen erkrankungen
US5948443A (en) *	1996-02-23	1999-09-07	Medical Doctor's Research Institute, Inc.	Acetylsalicylic acid and micronutrient supplementation for nutritional losses and coronary heart disease
US5654011A (en) *	1996-07-30	1997-08-05	Energetics, Inc.	Dietary supplements
US5897891A (en)	1996-11-18	1999-04-27	Godfrey; John C.	Flavorful zinc compositions for oral use incorporating copper
US5770215A (en)	1997-01-06	1998-06-23	Moshyedi; Emil Payman	Multivitamin/vascular occlusion inhibiting composition
US6428580B2 (en) *	1997-08-20	2002-08-06	L'oreal	Use of ascorbic acid in permanent waving and hair coloring compositions
US6316008B1 (en)	1998-09-03	2001-11-13	John C. Godfrey	Combination of zinc ions and vitamin C and method of making
DE19855426A1 (de) *	1998-12-02	2000-06-08	Wolfgang Langhoff	Mittel zur Therapie und Prophylaxe von rheumatisch-arthritischen Erkrankungen und zur Prophylaxe von cardiovaskulären Erkrankungen

2000
- 2000-10-02 PT PT00964469T patent/PT1220678E/pt unknown
- 2000-10-02 CA CA002386423A patent/CA2386423C/en not_active Expired - Lifetime
- 2000-10-02 JP JP2001527802A patent/JP2003510363A/ja active Pending
- 2000-10-02 US US10/089,846 patent/US7939109B1/en not_active Expired - Lifetime
- 2000-10-02 DK DK00964469T patent/DK1220678T3/da active
- 2000-10-02 EP EP00964469A patent/EP1220678B1/de not_active Expired - Lifetime
- 2000-10-02 DE DE60033830T patent/DE60033830T2/de not_active Expired - Lifetime
- 2000-10-02 AT AT00964469T patent/ATE355846T1/de active
- 2000-10-02 GB GB0024057A patent/GB2356347B/en not_active Expired - Fee Related
- 2000-10-02 ES ES00964469T patent/ES2283318T3/es not_active Expired - Lifetime
- 2000-10-02 AU AU75403/00A patent/AU776732B2/en not_active Expired
- 2000-10-02 WO PCT/GB2000/003770 patent/WO2001024803A2/en not_active Ceased
2004
- 2004-12-03 US US11/002,672 patent/US7758899B2/en not_active Expired - Fee Related
2007
- 2007-05-31 CY CY20071100726T patent/CY1106633T1/el unknown

Also Published As

Publication number	Publication date
DE60033830T2 (de)	2007-11-15
DK1220678T3 (da)	2007-07-09
EP1220678B1 (de)	2007-03-07
AU7540300A (en)	2001-05-10
CA2386423C (en)	2009-07-21
PT1220678E (pt)	2007-06-11
GB0024057D0 (en)	2000-11-15
ES2283318T3 (es)	2007-11-01
US20050123623A1 (en)	2005-06-09
CY1106633T1 (el)	2012-01-25
JP2003510363A (ja)	2003-03-18
AU776732B2 (en)	2004-09-23
EP1220678A2 (de)	2002-07-10
WO2001024803A3 (en)	2001-08-23
GB2356347B (en)	2002-05-15
GB2356347A (en)	2001-05-23
CA2386423A1 (en)	2001-04-12
WO2001024803A2 (en)	2001-04-12
US7939109B1 (en)	2011-05-10
DE60033830D1 (de)	2007-04-19
US7758899B2 (en)	2010-07-20

Legal Events

Date

Code

Title

Description

2007-09-15

UEP

Publication of translation of european patent specification

Ref document number: 1220678

Country of ref document: EP

Publication	Publication Date	Title
AU2019203820B2 (en)	2020-12-24	Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
ES2303860T3 (es)	2008-09-01	Compuesto de estroncio para el tratamiento del dolor en los tejidos blandos subcutaneos.
CA2600384C (en)	2016-08-30	Compositions and methods for treating acne
MA23170A1 (fr)	1994-12-31	Procede de preparation d'un nouveau compose .
ES2180646T3 (es)	2003-02-16	Formulaciones liquidas orales de alendronato.
ES2171933T3 (es)	2002-09-16	Derivados de androsteno.
DE69932939D1 (de)	2006-10-05	Fulvinsäure und dessen verwendung zur behandlung von diversen krankheitszuständen
ATE355846T1 (de)	2007-03-15	Pharmazeutische zusammensetzung, die kupfer, salicylsäure und vitamin c enthält
BR9406594A (pt)	1996-01-02	Formulação tópica e processos para sua preparação e para o tratamento e prevenção de parasitas internos e externos de animais
DE60018409D1 (de)	2005-04-07	Verwendung von antiseptika zur herstelllung von arzneimitteln zur prophylaxe und behandlung von infektionen und/ oder funktionellen gewebeumformungen im körperinneren
ES2124983T3 (es)	1999-02-16	Utilizacion de un antagonista de substancia p para el tratamiento de las manchas rojas cutaneas de origen neurogeno.
US6979468B1 (en)	2005-12-27	Oral composition and method for the treatment of inflammatory cutaneous disorders
GEP20043231B (en)	2004-05-25	Resorcinol Composition
CA2438164A1 (en)	2002-09-19	Use of preparations containing selenite or selenate
EP1297838A4 (de)	2003-07-09	Pralmorelin-haltige nasentropfen-präparate
RU99116693A (ru)	2001-05-10	Способ профилактики и лечения цитостатической и постлучевой лейкопении и анемии
RU2000126015A (ru)	2002-10-20	Лекарственное средство для лечения и профилактики болезней, вызываемых недостаточностью селена в организме сельскохозяйственных животных
DK0998929T3 (da)	2005-07-25	Topiske farmaceutiske sammensætninger til sårheling omfattende borneol og bismuthsubgallat
AU2015230725A1 (en)	2015-10-08	Methods of treating or ameliorating diseases and enhancing performance comprising the use of a magnetic dipole stabilized solution
BG106025U (en)	2003-04-30	Medicamentous form
IL110888A (en)	1999-07-14	Pharmaceutical compositions for the treatment of liver diseases comprising a vasodilating compound
RU93007470A (ru)	1997-02-27	Состав для профилактики и лечения инфекционных болезней конечностей копытных животных
BR0314518A (pt)	2005-07-26	Sais de metal multivalente de ácidos borÈnicos e seus usos no tratamento de trombose
UA42947A (uk)	2001-11-15	Спосіб лікування генералізованого пародонтиту